SCHEMBL753113

SCHEMBL753113

COCCNC(=O)Nc1ccc(Nc2nc3cccnn3c2-c2cc(N)nc(C)n2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 14/20 0.54
MTOR P42345 12/20 0.54
ALDH1A1 P00352 3/20 0.39
POLB P06746 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 2/20 0.39
MAPT P10636 2/20 0.39
KMT2A Q03164 2/20 0.39
LMNA P02545 1/20 0.39
PIK3CD O00329 1/20 0.37
PIK3CB P42338 1/20 0.37
PIK3CG P48736 1/20 0.37
APAF1 O14727 1/20 0.37
THRB P10828 1/20 0.37
PABPC1 P11940 1/20 0.37
PTPN7 P35236 1/20 0.37
RECQL P46063 1/20 0.37
DUSP3 P51452 1/20 0.37
BLM P54132 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11029150 0.89 PIK3CA (0.58) PIK3CAMTORPIK3CDPIK3CBPIK3CG
SCHEMBL11030367 0.83 PIK3CA (0.53) PIK3CAMTORALDH1A1KDM4EMAPT
SCHEMBL11029184 0.82 PIK3CA (0.56) PIK3CAMTORPDE4APDE4BPDE4C
SCHEMBL755704 0.82 PIK3CA (0.53) PIK3CAMTORALDH1A1KDM4EMAPT
SCHEMBL11029742 0.81 PIK3CA (0.70) PIK3CAMTORPIK3CDPIK3CBPIK3CG
SCHEMBL751191 0.80 PIK3CA (0.57) PIK3CAMTORPDE4APDE4BPDE4C
SCHEMBL751744 0.80 PIK3CA (0.57) PIK3CAMTORALDH1A1KDM4EPDE4A
SCHEMBL753756 0.79 PIK3CA (0.56) PIK3CAMTORALDH1A1SMN1; SMN2KDM4E
SCHEMBL754291 0.78 PIK3CA (0.55) PIK3CAMTORALDH1A1SMN1; SMN2KDM4E
SCHEMBL753798 0.78 PIK3CA (0.55) PIK3CAMTORALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP claimed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US claimed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP claimed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO claimed
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD PIK3CA 1/4885MTOR 21/4885ALDH1A1 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.